AREC vs. OBI, REDX, ETX, SBTX, COS, C4XD, DDDD, TRX, FUM, and OKYO
Should you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Ondine Biomedical (OBI), Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Tissue Regenix Group (TRX), Futura Medical (FUM), and OKYO Pharma (OKYO). These companies are all part of the "biotechnology" industry.
Arecor Therapeutics vs.
Arecor Therapeutics (LON:AREC) and Ondine Biomedical (LON:OBI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
44.1% of Arecor Therapeutics shares are held by institutional investors. Comparatively, 20.6% of Ondine Biomedical shares are held by institutional investors. 25.3% of Arecor Therapeutics shares are held by insiders. Comparatively, 36.7% of Ondine Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Ondine Biomedical has lower revenue, but higher earnings than Arecor Therapeutics. Ondine Biomedical is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.
Arecor Therapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. Comparatively, Ondine Biomedical has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.
Ondine Biomedical received 1 more outperform votes than Arecor Therapeutics when rated by MarketBeat users.
Arecor Therapeutics has a net margin of -176.89% compared to Ondine Biomedical's net margin of -873.84%. Arecor Therapeutics' return on equity of -118.67% beat Ondine Biomedical's return on equity.
In the previous week, Arecor Therapeutics had 6 more articles in the media than Ondine Biomedical. MarketBeat recorded 6 mentions for Arecor Therapeutics and 0 mentions for Ondine Biomedical. Arecor Therapeutics' average media sentiment score of 1.19 beat Ondine Biomedical's score of 0.00 indicating that Arecor Therapeutics is being referred to more favorably in the media.
Summary
Arecor Therapeutics beats Ondine Biomedical on 8 of the 14 factors compared between the two stocks.
Get Arecor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arecor Therapeutics Competitors List
Related Companies and Tools
This page (LON:AREC) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy AREC Stock Free AREC Stock Alerts